Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2

Conditions

Polycythemia Vera 2Thrombocythemia, Essential 1Primary Myelofibrosis 1

Interventions

Specimen Handling 613pembrolizumab 563Magnetic Resonance Spectroscopy 536Carboplatin 425Cisplatin 375Cyclophosphamide 373Biopsy 357Paclitaxel 306Gemcitabine 303Nivolumab 300Radiotherapy 260Bevacizumab 234Dexamethasone 209fludarabine 205Docetaxel 187durvalumab 182atezolizumab 173Oxaliplatin 172venetoclax 168Fluorouracil 166Rituximab 165Pemetrexed 163Capecitabine 158Doxorubicin 157Radiation 155Radiosurgery 148Etoposide 137Leucovorin 133Ipilimumab 133Lenalidomide 131

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × bomedemstat × 90 days × Clear all
NCT05558696 2026-05-07

IMG-7289-CTP-203

Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)

Phase 2 Completed
20 enrolled 19 charts
Myeloid

Polycythemia Vera

NCT06351631 2026-04-02

MK-3543-017

Merck Sharp & Dohme LLC

Phase 3 Recruiting
400 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡